Eli Lilly Reports Blowout Quarter As Obesity Drug Sales Accelerate


(MENAFN- Baystreet) Splash Makes Splash over Sea World Partnership

  • Honda Recall
  • DocuSign Announcing Layoffs
  • Clean Harbor Flat on Buying HEPACO
  • Trade Ideas: Intel, DocuSign, and More Previous Articles Subscribe to Get Small Cap News & Alerts Baystreet Staf - Tuesday, February 6, 2024

    Eli Lilly Reports Blowout Quarter As Obesity Drug Sales Accelerate

    U.S. pharmaceutical company Eli Lilly (LLY) has reported fourth-quarter financial results that blew past Wall Street estimates as sales of its new weight loss drug“Zepbound” accelerate.

    Eli Lilly announced Q4 earnings per share (EPS) of $2.49 U.S., which was well ahead of the $2.22 U.S. expected by analysts.

    Revenue in the final three months of 2023 totaled $9.35 billion U.S. compared to $8.93 billion U.S. that was forecast on Wall Street. Sales were up 28% from a year ago.

    The quarterly results were the first to include sales of Zepbound, which some analysts say could post more than $1 billion U.S. in sales in its first year on the market.

    Zepbound, which won regulatory approval last November, brought in $175.8 million U.S. in sales for Eli Lilly during last year's fourth and final quarter.

    The company is also getting a boost from its blockbuster diabetes drug Mounjaro, which also helps people to lose weight.

    Mounjaro posted $2.21 billion U.S. in Q4 sales, up from $279.2 million U.S. a year ago. Analysts expected the drug to bring in $1.73 billion U.S. in sales.

    Management at Eli Lilly have warned that they are struggling to keep up with demand for both Zepbound and Mounjaro.

    Shares of Eli Lilly were up 5% in premarket trading on news of its latest earnings print.

    Prior to today (Feb. 6), the stock of Eli Lilly had risen 109% in the last 12 months to trade at $706.20 U.S. per share.

    With a market capitalization of $670 billion U.S., Eli Lilly is now the largest pharmaceutical company in the U.S.





    • About Us
    • Contact Us
    • Advertise
    • License Our Content
    • Jobs
    • Disclaimer
    • Privacy Policy

    Copyright 1998 - 2024 Baystreet Media Corp. All rights reserved. Nasdaq Stocks: Information delayed 15 minutes. Non-Nasdaq Stocks: Information delayed 20 minutes. Bid and Ask quotation information for NYSE and AMEX securities is only available on a real time basis. Market Data is provided by QuoteMedia. Earnings by Zacks. Analyst Ratings by Zacks

    MENAFN06022024000212011056ID1107817390


  • Legal Disclaimer:
    MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.